Immutep Quarterly Activities Report

    NEXT STORY
    ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
    PREV STORY
    Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ADMA Biologics Further Enhances Intellectual Property Portfolio Through Newly Issued U.S. Patent for Immunotherapeutic Compositions

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, ...

    author_avatar
    NASDAQ Market News

    Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

    author_avatar
    NASDAQ Market News

    Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

    CRANBURY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that John ...

    author_avatar
    NASDAQ Market News